<?xml version="1.0" encoding="UTF-8"?>
<p>Many efforts are in progress to produce a vaccine for SARS-CoV-2. The approaches include the classical inactivated and attenuated vaccines (7 teams are working on this with two inactivated vaccines in clinical trials), the protein subunit and virus like particle vaccines (VLP) (28 teams on the subunit vaccines, mostly on the spike protein and 5 on VLPs), viral vector-based vaccines (~25 teams with one in clinical trial), as well as the newer DNA- and RNA-based vaccines (20 teams with one of each type in clinical trials) [
 <xref rid="B56-viruses-12-00526" ref-type="bibr">56</xref>]. Each approach has its own advantages and disadvantages and all approaches are being developed simultaneously to come up with an effective vaccine (reviewed in Amanat and Krammer, 2020) [
 <xref rid="B57-viruses-12-00526" ref-type="bibr">57</xref>].
</p>
